At the present time, measures of endothelial cell function and biocompatibility have advanced our understanding of the pathophysiology of atherosclerosis and its treatment. They are quickly becoming well-established surrogates of disease activity; however, the ideal test(s) of endothelial function have yet to be established. As we incorporate new biomarkers into global risk assessment, the endothelium is the logical target of study, given its unique position as both a sensor and participant in the atherosclerosis process. Recent evidence suggests that the mechanistic basis for the powerful predictive value of inflammatory biomarkers such as CRP may also reside at the level of the endothelium. Although endothelial function testing remains a research tool at the present time, it is our contention that this technology will figure prominently in risk assessment strategies in the future.
CITATION STYLE
Verma, S., Buchanan, M. R., & Anderson, T. J. (2003, October 28). Endothelial Function Testing as a Biomarker of Vascular Disease. Circulation. https://doi.org/10.1161/01.CIR.0000089191.72957.ED
Mendeley helps you to discover research relevant for your work.